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Summary Organ transplant recipients receiving immunosuppression show a dramatically increased risk of non-melanoma skin cancer. The
cause of this increase is not known. We report that the rate of loss of heterozygosity (at all the loci we examined) was significantly lower in
tumours from immunosuppressed individuals than in tumours from immunocompetent subjects [20 out of 148 (14%) vs 157 out of 428 (37%);
P < 0.0001]. These results suggest that tumours in immunosuppressed individuals have a different molecular pathogenesis.
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Patients receiving immunosuppressive therapy after organ trans-
plantation show up to a 250-fold increase in the incidence of non-
melanoma skin cancers (NMSCs) and their precursor lesions
(Abel, 1989; Hartevelt et al, 1990; Espana et al, 1995; Glover et al,
1997). In such patients the high prevalence ofinfection by a spec-
trum of human papilloma virus (HPV) types together with a high
incidence of other neoplasms associated with a viral pathogenesis
has suggested a role for virus during NMSC development (Barr et
al, 1989). However, in skin, unlike cervical carcinoma, compelling
evidence that HPVs play a causative role, rather than being mere
passengers, is lacking. It is also possible that other viruses such as
the recently described Kaposi's sarcomaherpes-like virus (KSHV)
(Boshoff et al, 1996) or as yet unidentified viruses may be impor-
tant. We therefore sought indirect evidence for a different molec-
ular pathogenesis in these tumours that would provide support for
a causal role for one or more types ofvirus, including viruses that
had not yet been identified.
Tumour-suppressor gene inactivation commonly occurs by
mutation of one allele accompanied by chromosome loss of the
wild-type allele (Knudson, 1991). Other mechanisms of tumour-
suppressor gene activation can occur, including binding of the
products of virally encoded oncogenes or changes in methylation
status of tumour-suppressor genes (Vousden, 1993; Kinzler and
Vogelstein, 1996). If, in tumours from immunosuppressed individ-
uals, tumour-suppressor genes are being inactivated by alternative
means, then the rate or pattern of loss of heterozygosity might be
expected to differ from those in immunocompetent individuals.
We examined this hypothesis.
METHODS
Paraffin-embedded material from 32 cutaneous tumours [17 squa-
mous cell carcinomas (SCCs) and 15 in situ lesions (Bowen's
disease and actinic keratoses)] from 12 patients who had received
Received 30 September 1996
Revised 6 March 1997
Accepted 11 March 1997
Correspondence to: JL Rees, Department of Dermatology, Medical School,
University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK
cardiac or renal transplants and were receiving immunosuppres-
sive therapy with prednisone, azathioprin and cyclosporin were
compared with 96 tumours from 68 immunocompetent individuals
comprising 23 SCCs and 73 in situ lesions. All 'transplant'
tumours were from patients who had received over 3 years of
immunosuppression. Histology specimens were reviewed by an
expert dermatopathologist (MT). The non-transplant SCC group
comprised two poorly differentiated, 11 moderately differentiated
and seven well-differentiated carcinomas and three other SCC
types, compared with two poorly differentiated, four moderately
differentiated, nine well-differentiated carcinomas and two other
SCC types from the transplant patient group.
Ten-micrometre tissue sections werecarefully microdissected to
separate tumour from adjacent normal epithelium, and the DNA
was extracted using phenol-chloroform (Jackson et al, 1995). In
all cases, control DNA from either adjacent normal skin or blood
was used. Tumour and control DNA was subject to polymerase
chain reaction (PCR) amplification using one [y-32P]ATP (Life
Sciences, Amersham, UK) end-labelled primer as previously
described (Rehman et al, 1996), using microsatellite markers 3p
(D3S1293), 9p (D9S162, D9S171), 9q (D9S197), 13q (D13S170),
17p (D17S796) and 17q (D17S785) (Research Genetics,
Huntsville, AL, USA). PCR products were resolved on a 6% poly-
acrylamide gel and then fixed and dried; the bands were visualized
by autoradiography and the LOH was scored by eye.
Statistical comparisons were made using theX2 test and Fisher's
exact test.
RESULTS
The overall LOH forthe six loci examined was significantly lower
in tumours from transplant individuals than in control tumours
[LOH in 20 outof 148 (14%) vs 157 out of428 (37%), P<0.0001]
(see Table 1). Examination of the pattern of loss by chromosome
arm shows that the differences wereparticularly marked for 3p and
13q as well as for 17p and 17q. Examples ofallelic loss are shown
in Figure 1. The difference between the patient groups was evident
for both invasive and in situ lesions (transplant SCC vs control
SCC, P = 0.002; transplant in situ lesions vs control in situ lesions,
P = 0.008).
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Table 1 Frequency of LOH at individual loci in cutaneous tumours from transplant and non-transplant patients
Transplant tumours (n = 32) Non-transplant tumours (n = 96)
Chromosome arm Alleles lost Alleles retained LOH (%) Alleles lost Alleles retained LOH (%)
3p 1 26 4 20 47 30
9p 5 20 20 24 55 30
9q 2 22 8 8 51 14
13q 4 20 17 37 39 49
17p 7 20 26 41 28 59
17q 1 20 5 27 51 35
Total LOH (six loci) 20 128 14 157 271 37
DISCUSSION
The lower rate of LOH in tumours occurring in immunosup-
pressed individuals is compatible with these tumours having a
different molecular pathogenesis. Studies relevant to the interpre-
tation of the results have been reported for other tumour types.
Busby-Earle et al (1993) showed that the rate of LOH in cervical
carcinoma (in which there is thought to be a viral pathogenesis)
was lower than in some other solid tumours. Interpretation ofthese
results is however difflcult as comparisons were made between
tumours from different organs. Similarly, rates of p53 mutation
have been reported to be low in cervical cancers in which HPV
was detected (compared with tumours in which virus was not
detected) in some, but not all, studies of cervical carcinoma, the
implication being that viral products may inactivate the p53
tumour-suppressor genes by alternative mechanisms to mutation
(Crook et al, 1991; Busby-Earle et al, 1992; Vousden, 1993).
Transplant recipients receiving immunosuppression show an
elevated risk of various tumour types that have in common a
possible viral pathogenesis, including lymphoma, cervix and
Kaposi's sarcoma of the skin (Kinlen et al, 1979; London et al
1995). Given the increased risk ofNMSC and the high prevalence
of HPV infection, it is therefore tempting to imagine that
HPV cause NMSC. However, unlike the situation in cervix, a
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Figure 1 Examples of allelic deletions in in situ lesions, using microsatellite
polymorphism Dl7S796 (17p). Lanes 1 and 2, patient 1; 3 and 4, patient 2; 5
and 6, patient 3; 7 and 8, patient 4. Controls: lanes 1, 3, 5 and 7. Allelic
losses are seen in lanes 4 and 6, but not in lane 2. Patient 4 is uninformative
mechanism for such a role is not known (Vousden, 1993). Other
non-HPV viruses could also be aetiologically important.
Resolving this question is difficult because of the large number of
human papillomaviruses, ignorance of their potential pathogenic
mechanisms and the problem of providing evidence for other as
yet uncharacterized viruses (Stark et al, 1994; Tieben et al, 1994).
The results presented, while compatible with a role for viral
pathogenesis, are puzzling in at least one respect. If only one
particular tumour-suppressor gene was involved, then one would
imagine that a particular viral product would interact with this
pathway, and one would not expect to see a difference in LOH at
all the loci examined. On the contrary, the finding ofdifferences at
multiple loci suggests that if the explanation lies with a putative
virus, then this virus is capable of inactivating several tumour-
suppressor genes. Alternatively, and perhaps more interestingly,
tumours in immunosuppressed individuals in which there may be
decreased immunosurveillance may be able to bypass the need to
inactivate certain tumour-suppressor genes.
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